Preoperative hydronephrosis as a predictor of postnephroureterectomy survival in patients with upper tract urothelial carcinoma: a two-center study in Japan.


Journal

International journal of clinical oncology
ISSN: 1437-7772
Titre abrégé: Int J Clin Oncol
Pays: Japan
ID NLM: 9616295

Informations de publication

Date de publication:
Mar 2020
Historique:
received: 31 05 2019
accepted: 22 08 2019
pubmed: 5 9 2019
medline: 12 6 2020
entrez: 5 9 2019
Statut: ppublish

Résumé

To evaluate the predictive value of preoperative hydronephrosis for pathological outcome and prognosis in patients with upper tract urothelial carcinoma treated with nephroureterectomy. 167 patients with UTUC treated with nephroureterectomy at our two institutions in Japan between 2002 and 2017 were retrospectively analyzed. Preoperative computed tomography scans were evaluated for the presence of ipsilateral hydronephrosis. Preoperative hydronephrosis's associations with pathological outcome and postnephroureterectomy survival were assessed. Ipsilateral hydronephrosis was present in 102 patients (61.1%). Preoperative hydronephrosis was not associated with higher pathological T stage (T3 or greater). Patients with preoperative hydronephrosis compared with patients without preoperative hydronephrosis had significantly worse recurrence-free survival (RFS) (5-year survival, 61.9% and 77.6%, respectively; p = 0.033), disease-specific survival (DSS) (5-year survival, 66.9% and 88.1%, respectively; p = 0.026), and overall survival (OS) (5-year survival, 54.5% and 80.6%, respectively; p = 0.030). A multivariate Cox regression model identified preoperative hydronephrosis and higher clinical T stage (T3 or greater) as an independent predictor of shorter RFS (p = 0.015 and 0.0009, respectively). We segregated the patients into three risk groups based on the number of these two prognostic factors: 0, favorable risk; 1, intermediate risk; 2, poor risk. The favorable-risk group had significantly better RFS (p = 0.0003), DFS (p = 0.0001), and OS (p = 0.0007) than the poor and intermediate-risk groups (RFS (p = 0.0011), DFS (p = 0.0017), and OS (p = 0.0043)). The presence of preoperative hydronephrosis was a significant risk factor affecting survival. Our risk classification based on preoperative hydronephrosis and clinical T stage may be helpful for patient counselling and decision-making before nephroureterectomy.

Identifiants

pubmed: 31482240
doi: 10.1007/s10147-019-01535-6
pii: 10.1007/s10147-019-01535-6
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

456-463

Références

Cancer. 2009 Mar 15;115(6):1224-33
pubmed: 19156917
J Urol. 2005 Dec;174(6):2120-3; discussion 2124
pubmed: 16280740
Urol Oncol. 2014 Oct;32(7):981-8
pubmed: 25022858
J Urol. 1998 Dec;160(6 Pt 1):2011-4
pubmed: 9817312
J Urol. 2007 Oct;178(4 Pt 1):1212-7; discussion 1217
pubmed: 17698147
Ann Surg Oncol. 2013 Dec;20(13):4389-96
pubmed: 24046115
J Urol. 2011 May;185(5):1621-6
pubmed: 21419429
World J Urol. 2013 Feb;31(1):155-60
pubmed: 22614444
N Engl J Med. 2003 Aug 28;349(9):859-66
pubmed: 12944571
Eur Urol. 2007 Mar;51(3):690-7; discussion 697-8
pubmed: 16904815
J Clin Oncol. 2017 Mar 10;35(8):852-860
pubmed: 28045620
Eur Urol. 2012 Jul;62(1):100-14
pubmed: 22381168
Urol Oncol. 2013 May;31(4):407-13
pubmed: 20884249
Urology. 2008 Aug;72(2):379-83
pubmed: 18514771
PeerJ. 2016 Jun 21;4:e2144
pubmed: 27366646
Oncol Lett. 2015 Nov;10(5):3113-3122
pubmed: 26722298
J Urol. 2012 Feb;187(2):429-34
pubmed: 22177163
Cancer. 2010 Jul 1;116(13):3127-34
pubmed: 20564621
Int Urol Nephrol. 2013 Feb;45(1):99-106
pubmed: 23229166
Jpn J Clin Oncol. 2012 Mar;42(3):202-7
pubmed: 22246718
CA Cancer J Clin. 2013 Jan;63(1):11-30
pubmed: 23335087
J Clin Oncol. 2011 Jun 1;29(16):2171-7
pubmed: 21502557
Eur Urol. 2015 Nov;68(5):868-79
pubmed: 26188393
J Urol. 2012 Mar;187(3):845-51
pubmed: 22248522
Eur Urol. 2008 Apr;53(4):794-802
pubmed: 18207313

Auteurs

Tomohiro Fukui (T)

Department of Urology, Hamamatsu Rosai Hospital, 25 Shogen-machi, Higashi-ku, Hamamatsu, Shizuoka, 430-8525, Japan. tomoftakatuki@yahoo.co.jp.
Department of Urology, Rakuwakai Otowa Hospital, 2 Otowatinji-machi, Yamashina-ku, Kyoto, Kyoto, 607-8062, Japan. tomoftakatuki@yahoo.co.jp.

Toru Kanno (T)

Department of Urology, Ijinkai Takeda General Hospital, 28-1 Ishidamoriminami-cho, Fushimi-ku, Kyoto, Kyoto, 601-1495, Japan.

Go Kobori (G)

Department of Urology, Hamamatsu Rosai Hospital, 25 Shogen-machi, Higashi-ku, Hamamatsu, Shizuoka, 430-8525, Japan.

Seiji Moroi (S)

Department of Urology, Hamamatsu Rosai Hospital, 25 Shogen-machi, Higashi-ku, Hamamatsu, Shizuoka, 430-8525, Japan.

Hitoshi Yamada (H)

Department of Urology, Ijinkai Takeda General Hospital, 28-1 Ishidamoriminami-cho, Fushimi-ku, Kyoto, Kyoto, 601-1495, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH